Browsing Health Sciences by Author "Petzer, J.P."
Now showing items 1-20 of 34
-
Design and synthesis of heterocyclic compounds for neuroprotective enzyme interactions
Prins, Louis Hendrik Albertus (North-West University, 2010)Neurodegenerative diseases are thought to be multifactorial in nature and therefore current research focus has shifted from a ‘one-drug-one-target’ approach to that of multitarget directed ligands (MTDLs). These ligands ... -
Design, synthesis and evaluation of 3-hydroxypyridin-4-ones as inhibitors of catechol-O-methyltransferase
De Beer, Johannie (2015)Parkinson’s disease is a bradykinetic disorder that is the result of the death of dopaminergic neurons in the basal ganglia of the brain. This, in turn, leads to the depletion of dopamine in the striatum, which is responsible ... -
The design, synthesis and evaluation of aminocaffeine derivatives as inhibitors of monoamine oxidase B
Moraal, Christina Maria (North-West University, 2011)Monoamine oxidase (MAO) is responsible for dopamine catabolism in the brain and therefore is especially important in the treatment of Parkinson's disease (PD). MAO–B inhibition provides symptomatic relief by indirectly ... -
Evaluation of nitrocatechol bearing cyclic chalcones and related analogues as dual monoamine oxidase and catechol-O-methyltransferase inhibitors
De Beer, Andries Daniël (North-West University (South-Africa), 2020)Parkinson’s disease (PD) is one of the leading causes of disability in the world. A better understanding of the aetiology of this disorder will lead to better medications, and would improve the quality of life for millions ... -
Evaluation of selected dye compounds as inhibitors of enzymes, relevant to neurological disorders
Cloete, S.J. (North-West University (South-Africa), 2021)Neurological disorders such as Alzheimer’s disease, Parkinson’s disease and schizophrenia are disorders that affect a large part of the population, especially the elderly. The cause of these disorders is still not completely ... -
Evaluation of selected dye compounds as inhibitors of monoamine oxidase
De Beer, Franciska (North-West University (South-Africa), 2019)Parkinson’s disease (PD) and Alzheimer’s disease (AD) are neurodegenerative diseases that significantly impact the quality of life of patients. The pathology of Parkinson’s disease is characterised by neuronal death of the ... -
Identification of monoamine oxidase inhibitors using a molecular modelling approach
Pienaar, Anke (2014)Monoamine oxidase (MAO) is an enzyme located on the outer mitochondrial membrane and is considered to be a target for the treatment of diseases such as Parkinson’s disease and depression. MAO may be classified into two ... -
In silico screening, synthesis and in vitro determination of the biological activities of D-amino acid oxidase inhibitors
Bester, Elizabeth Magdalena (North-West University (South-Africa), 2022)Schizophrenia is a mental disorder with many clinical and therapeutic challenges. Current therapy is based on outdated pathological theories while most antipschycotic drugs have a significant side effect profile. New ... -
In vitro and in silico antimicrobial evaluation of N- methyl-2-phenylmaleimides
Fourie, Carla-Christie (North-West University (South-Africa), 2023)Due to COVID-19, many other pandemics have been overlooked in the past few years. Antimicrobial resistance (AMR) is a pandemic that have killed more people than Human Immunodeficiency Virus (HIV) and malaria in 2019 and ... -
Inhibition of monoamine oxidase B by substituted coumarin derivatives
Repsold, Benjamin Petrus (North-West University, 2008)Interest in the selective inhibition of monoamine oxidase B (MAO-B) has increased in the last years due to their therapeutic potential in age related neurodegenerative diseases such as Alzheimer's disease and Parkinson's ... -
Inhibition of monoamine oxidase by caffeine– and phthalide analogues
Strydom, Belinda (North-West University, 2012)Monoamine oxidase (MAO) consists of two isoforms, MAO-A and MAO-B. MAO is responsible for the oxidation of neurotransmitter and dietary amines. The MAO-B isoform, in particular, is considered to be a drug target for the ... -
Inhibition of monoamine oxidase by selected 8–[(phenylsulfanyl)methyl]caffeine derivatives
Okaecwe, Thokozile Audrey Dorcas (North-West University, 2012)Purpose: Monoamine oxidase (MAO) consists of two isoforms, namely MAO-A and MAO-B. Both these isoforms are involved in the oxidation of dopamine. In Parkinson’s disease (PD) therapy, the inhibition of the oxidation of ... -
The monoamine oxidase B substrate properties of selected pyrrolinyl analogues
Pretorius, Anél (North-West University, 2008)The parkinsonian inducing agent, 1-rnethyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), is a cyclic tertiary allylamine that is oxidized by monoamine oxidase B (MAO-B) at the ring a-carbon to yield the 1-rnethyl-4-pheny ... -
Monoamine oxidase inhibition by indanone and benzoquinone analogues
Mostert, Samantha (North-West University (South Africa) , Potchefstroom Campus, 2015)Parkinson’s disease (PD) is a neurological disorder of which aging is the greatest risk factor. Over the next fifteen years, the number of persons affected by PD worldwide is expected to increase from 4.6 million to 9.3 ... -
Monoamine oxidase inhibition by novel quinolinones
Meiring, Letitia (2014)Parkinson’s disease (PD) is an age-related neurodegenerative disorder. The degeneration of the neurons of the substantia nigra in the midbrain leads to the loss of dopamine from the striatum, which is responsible for the ... -
The monoamine oxidase inhibition properties of caffeine analogues containing saturated C–8 substituents
Grobler, Paul Johan (North-West University, 2010)Parkinson’s disease (PD) is a progressive neurodegenerative disorder, characterized pathologically by a marked loss of dopaminergic nigrostriatal neurons and clinically by disabling movement disorders. PD can be treated ... -
Monoamine oxidase inhibitory activities of heterocyclic chalcones
Minders, Corné (2013)Parkinson’s disease is the second most common age-related neurodegenerative disease after Alzheimer’s disease. The characteristic pathological feature of Parkinson’s disease is the loss of neurons in the substantia nigra ... -
Novel sulfanyl– and sulfinylcaffeine analogues as inhibitors of monoamine oxidase
Mentz, Wayne (North-West University, 2013)Parkinson’s disease (PD) is a neurodegenerative disorder, which is progressive in nature and usually associated with the elderly. It is the second most common age-related neurodegenerative disorder after Alzheimer’s disease ... -
The preparation and evaluation of xanthinyl analogues as inhibitors of monoamine oxidase B
Zoellner, Kevin Robert (North-West University, 2006)Monoamine oxidase B (MAO-B) is a drug target for the treatment of neurodegenerative diseases such as Parkinson's disease. For example, the mechanism-based inactivator of MAO-B, (R)-deprenyl, is frequently used in combination ... -
Rational approaches towards the design of (E)-8-(3-Chlorostyryl)-caffeine derivatives as novel reversible inhibitors of monoamine oxidase B
Vlok, Nevil (North-West University, 2005)Reversible and selective inhibitors of monoamine oxidase B (MAO-B) are under investigation for the treatment and prevention of Parkinson's disease (PD) and Alzheimer's disease. The mechanism-based inactivator of MAO-B, ...